QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.097170v1 jpet.105.097170v2 317/2/830    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Buccellati, C. Articles by Casagrande, C. Search for Related Content PubMed PubMed Citation Articles by Buccellati, C. Articles by Casagrande, C.

CARDIOVASCULAR

Pharmacological Characterization of 2NTX-99 [4-Methoxy-N¹-(4-trans-nitrooxycyclohexyl)-N³-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a Potential Antiatherothrombotic Agent with Antithromboxane and Nitric Oxide Donor Activity in Platelet and Vascular Preparations

Department of Pharmacological Sciences, School of Pharmacy, University of Milano, Milano, Italy

Thromboxane (TX) A₂, prostacyclin (PGI₂), and nitric oxide (NO) regulate platelet function and interaction with the vessel wall. Inhibition of TXA₂, implemented synthesis of PGI₂, and supply of exogenous NO may afford therapeutic benefit. 2NTX-99 [4-methoxy-N¹-(4-trans-nitrooxycyclohexyl)-N³-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a new chemical entity related to picotamide, showed antithromboxane activity and NO donor properties. 2NTX-99 relaxed rabbit aortic rings precontracted with norepinephrine or U46619 [GenBank] (9,11-dideoxy-9,11-methanoepoxy-prosta-5Z,13E-dien-1-oic acid; EC₅₀, 7.9 and 17.1 µM, respectively), an effect abolished by 10 µM 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ). 2NTX-99 inhibited arachidonic acid (AA)-induced washed platelet aggregation (EC₅₀, 9.8 µM) and TXB₂ formation (-71% at 10 µM), and its potency increased in the presence of aortic rings (EC₅₀, 1.4 µM). In whole rabbit aorta incubated with homologous platelets, AA caused contraction and TXA₂ formation, reduced by 2NTX-99 (10-40 µM): contraction, -28 and -47%, TXA₂ formation, -37 and -75.4%, respectively, with concomitant increase in PGI₂. 2NTX-99 (20-40 µM) inhibited U46619 [GenBank] -induced aggregation in rabbit platelet-rich plasma (PRP) (-74 ± 6.7 and -96 ± 2.4%, respectively) and inhibited collagen-induced aggregation in human PRP (-48.2 ± 10 and -79.2 ± 6%), whereas ozagrel was ineffective. In human embryonic kidney 293 cells transfected with the TXA₂ receptor isophorm receptor, 2NTX-99 did not compete with the ligand, [³H]SQ29,548 ([³H][1S-[1,2(5Z),3,4]]-7-[3-[[2-(phenylamino)-carbonyl]hydrazino]methyl]-7-oxabicyclo[2,2,1]-hept-2-yl]-5-heptanoic acid), or prevent inositol phosphate accumulation. After oral administration (50-250 mg/kg), 2NTX-99 inhibited TXA₂ production in rat clotting blood (-71 and -91%); at 250 mg/kg, an area under the curve, 0 to 16 h, of 149.5 h/µg/ml and a t_1/2 of 6 h were calculated, with a C_max value of 31.8 ± 8.2 µg/ml. An excellent correlation between plasma concentrations and TXA₂ inhibition occurs. 2NTX-99 controls platelet function and vessel wall interaction by multifactorial mechanisms and possesses therapeutic potential.

Address correspondence to: Dr. Giancarlo Folco, Department of Pharmacological Sciences, Center for Cardiopulmonary Pharmacology, School of Pharmacy, Via Balzaretti 9, 20133 Milano, Italy. E-mail: giancarlo.folco{at}unimi.it